Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
KALV Stock Chart & Stats
$14.60
-$0.39(-4.51%)
At close: 4:00 PM EST
$14.60
-$0.39(-4.51%)
Day’s Range― - ―
52-Week Range$8.19 - $19.00
Previous CloseN/A
Volume49.40K
Average Volume (3M)1.31M
Market Cap
$756.17M
Enterprise ValueN/A
Total Cash (Recent Filing)$309.16M
Total Debt (Recent Filing)$149.59M
Price to Earnings (P/E)―
Beta0.85
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding50,546,290
10 Day Avg. Volume860,242
30 Day Avg. Volume1,305,035
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)7.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.47
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$34.38Price Target Upside135.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Launch PerformanceAnalyst reports that initial Ekterly sales materially exceeded expectations, signaling stronger-than-anticipated patient demand and potential for sustained revenue expansion.
Physician AdoptionTop hereditary angioedema specialists and a growing number of unique prescribers have begun writing for Ekterly, indicating widening physician acceptance and deeper market penetration.
Product Convenience And Competitive PositioningEkterly's oral, self-administered profile combined with high patient satisfaction positions it as a convenient on-demand alternative that could displace injectable options.
Bears Say
Payer And Access UncertaintyUncertainty about payer quantity limits and refill policies may constrain real-world access and reduce long-term consumption per patient.
Refill-driven Demand RiskSales appear driven more by refills than new patient starts, creating risk that revenue growth could slow if new-prescription momentum does not pick up.
Transparency And Visibility LimitationsLimited disclosure on inventory levels and payer performance metrics reduces visibility into sustainable organic revenue and complicates forecasting.
KalVista Pharmaceuticals News
KALV FAQ
What was KalVista Pharmaceuticals’s price range in the past 12 months?
KalVista Pharmaceuticals lowest stock price was $8.19 and its highest was $19.00 in the past 12 months.
What is KalVista Pharmaceuticals’s market cap?
KalVista Pharmaceuticals’s market cap is $756.17M.
When is KalVista Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were KalVista Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is KalVista Pharmaceuticals overvalued?
According to Wall Street analysts KalVista Pharmaceuticals’s price is currently Undervalued.
Does KalVista Pharmaceuticals pay dividends?
KalVista Pharmaceuticals does not currently pay dividends.
What is KalVista Pharmaceuticals’s EPS estimate?
KalVista Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals has 50,546,290 shares outstanding.
What happened to KalVista Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of KalVista Pharmaceuticals?
Currently, no hedge funds are holding shares in KALV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
KalVista Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.38 (135.48% Upside)
$34.38 (135.48% Upside)
Blogger Sentiment
Neutral
KALV Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
71.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.17%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
KALV Earnings Call
Q3 2025
0:00 / 0:00
KALV Stock 12 Month Forecast
Average Price Target
$34.38
▲(135.48% Upside)
Technical Analysis
Savara
―
Arvinas Holding Company
―
Gossamer Bio
―
Compass Therapeutics
―
Bicara Therapeutics Inc.
―
Ownership Overview
Currently, No data available
---